❌

Reading view

Berry-derived gold nanoparticles induce integrated ROS-mediated apoptosis, immune modulation, and transcriptomic remodeling in 4T1 triple-negative cancer cells

Cell Death Discovery, Published online: 10 April 2026; doi:10.1038/s41420-026-03023-z

Berry-derived gold nanoparticles induce integrated ROS-mediated apoptosis, immune modulation, and transcriptomic remodeling in 4T1 triple-negative cancer cells
  •  

Predicting bilingual aphasia treatment outcomes using digital twins: a double-blind randomized controlled trial

npj Digital Medicine, Published online: 10 April 2026; doi:10.1038/s41746-026-02583-9

Predicting bilingual aphasia treatment outcomes using digital twins: a double-blind randomized controlled trial
  •  

The importance of competition and facilitation for global tree diversity

Nature, Published online: 08 April 2026; doi:10.1038/s41586-026-10349-2

Across 17 forest plots (2.7 million trees, 5,400 species), competition dominated overall, but facilitation was relatively stronger near the equator and declined towards higher latitudes, partly linked to temperature, legumes, mycorrhizal associations and canopy nursing effect.
  •  

DNA damage drives antigen diversification in <i>Trypanosoma brucei</i>

Nature, Published online: 08 April 2026; doi:10.1038/s41586-026-10337-6

An in vitro toolkit for studying VSG diversification defines key molecular requirements underlying the formation of mosaic VSGs, providing an experimental framework for the exploration of antigen diversification in Trypanosoma brucei and in other pathogenic microorganisms.
  •  

Single-cell spatiotemporal dissection of the human maternal–fetal interface

Nature, Published online: 08 April 2026; doi:10.1038/s41586-026-10316-x

A single-cell multiomic atlas of the human maternal–fetal interface across pregnancy reveals cell types, states and spatial niches, developmental tissue architectures and transcriptional programmes, and identifies cell types with roles in pre-eclampsia, spontaneous preterm birth and miscarriage.
  •  

High-precision measurement of the W boson mass with the CMS experiment

Nature, Published online: 08 April 2026; doi:10.1038/s41586-026-10168-5

The CMS experiment at CERN reports one of the highest-precision measurements of the W boson mass, finding it in line with standard model predictions and at odds with recent anomalous measurements.
  •  

Mummified early Permian reptile reveals ancient amniote breathing apparatus

Nature, Published online: 08 April 2026; doi:10.1038/s41586-026-10307-y

A mummified fossil of the early Permian reptile Captorhinus reveals the potential ancestral amniote breathing mechanism and its impact on terrestrial vertebrate evolution.
  •  

Multiomics and deep learning dissect regulatory syntax in human development

Nature, Published online: 08 April 2026; doi:10.1038/s41586-026-10326-9

The Human Development Multiomic Atlas catalogues single-cell accessibility and gene expression data from human fetal cells across 12 organs, enabling the inference of syntactic rules for motifs that govern cell-type-specific transcription factor binding and chromatin accessibility during human development.
  •  

Population-scale repeat expansions elucidate disease risk and brain atrophy

Nature, Published online: 08 April 2026; doi:10.1038/s41586-026-10345-6

Decreased brain volumes and increased NfL levels can be observed earlier than disease diagnosis in short-tandem-repeat-associated neurological diseases.
  •  

Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial

Nature Medicine, Published online: 07 April 2026; doi:10.1038/s41591-026-04307-8

In a phase 1 basket trial, the small interfering RNA zodasiran, targeting ANGPTL3, lowered triglycerides in patients with severe hypertriglyceridemia and lowered both triglycerides and low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia.
  •  

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04282-0

In the phase 3 EMN24 IsKia trial, transplant-eligible patients with newly diagnosed multiple myeloma who received isatuximab with carfilzomib, lenalidomide and dexamethasone pretransplant induction and post-transplant consolidation showed higher rates of measurable residual disease negativity after consolidation than patients who received carfilzomib, lenalidomide and dexamethasone.
  •  
  •  
❌